1-[9-(carboxymethyl)-2-[4-(4-hydroxyphenyl)piperazin-1-yl]purin-6-yl]indazole-4-carboxylic acid
C25H22N8O5 — CID 155103037
Data last refreshed: (MolForge compound catalog, from PubChem)
About 1-[9-(carboxymethyl)-2-[4-(4-hydroxyphenyl)piperazin-1-yl]purin-6-yl]indazole-4-carboxylic acid
1-[9-(carboxymethyl)-2-[4-(4-hydroxyphenyl)piperazin-1-yl]purin-6-yl]indazole-4-carboxylic acid (PubChem CID 155103037) has the molecular formula C25H22N8O5 and a molecular weight of 514.50 g/mol. Its IUPAC name is 1-[9-(carboxymethyl)-2-[4-(4-hydroxyphenyl)piperazin-1-yl]purin-6-yl]indazole-4-carboxylic acid.
Molecular Properties
| Compound Name | 1-[9-(carboxymethyl)-2-[4-(4-hydroxyphenyl)piperazin-1-yl]purin-6-yl]indazole-4-carboxylic acid |
|---|---|
| PubChem CID | 155103037 |
| Molecular Formula | C25H22N8O5 |
| Molecular Weight | 514.50 g/mol |
| Exact Mass | 514.17 |
| IUPAC Name | 1-[9-(carboxymethyl)-2-[4-(4-hydroxyphenyl)piperazin-1-yl]purin-6-yl]indazole-4-carboxylic acid |
| SMILES | O=C(O)Cn1cnc2c(-n3ncc4c(C(=O)O)cccc43)nc(N3CCN(c4ccc(O)cc4)CC3)nc21 |
| InChI | InChI=1S/C25H22N8O5/c34-16-6-4-15(5-7-16)30-8-10-31(11-9-30)25-28-22-21(26-14-32(22)13-20(35)36)23(29-25)33-19-3-1-2-17(24(37)38)18(19)12-27-33/h1-7,12,14,34H,8-11,13H2,(H,35,36)(H,37,38) |
| InChIKey | MRMDGEKKDMKLSM-UHFFFAOYSA-N |
| XLogP | 1.98 |
| TPSA | 162.73 Ų |
| H-Bond Donors | 3 |
| H-Bond Acceptors | 11 |
| Rotatable Bonds | 6 |
| Heavy Atoms | 38 |
| Complexity | — |
Lipinski Rule of Five
2 violations
| Rule | Value |
|---|---|
| MW ≤ 500 | 514.50 |
| LogP ≤ 5 | 1.98 |
| H-Bond Donors ≤ 5 | 3 |
| H-Bond Acceptors ≤ 10 | 11 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 155103037 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.